Xi'an Faithful BioTech Co., Ltd. is selling Ivermectin. Please feel free to contact us if you have any purchase needs.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Industry Foundation: Core Definition and Origin Evolution of Ivermectin
1.1 Core Definition and Material Properties
Ivermectin is a broad-spectrum antiparasitic active ingredient, belonging to the macrolide class of compounds. It is produced by the fermentation of Streptomyces avermitilis. Its chemical structure is mainly composed of 80% B1a and no more than 20% B1b. This component ratio directly determines its efficacy and safety, and is one of the core indicators for quality control in the industry. This ingredient has high bioselectivity, enabling it to precisely target the nervous system and muscle tissue of parasites. By interfering with ion channel permeability and synaptic transmission processes, it achieves effective control of parasites. Furthermore, because it cannot penetrate the human blood-brain barrier, it has a high safety profile for humans. As a core category in the global antiparasitic field, ivermectin is included in the World Health Organization's (WHO) List of Essential Medicines and in China's National Essential Medicines List, and is widely used in public health, livestock farming, skin health, and other fields.
1.2 Origins and Development Milestones
The discovery and industrialization of ivermectin represents a significant breakthrough in the field of bio-fermentation. In 1975, a research team from Kitasato University in Japan and Merck & Co. in the United States first isolated *Streptomyces avermitosa* from soil in Shizuoka Prefecture, Japan, and successfully fermented it to obtain avermectin-like compounds. Ivermectin, as a hydrogenated derivative of avermectin, became a key focus of research due to its superior stability and bioactivity. In 1978, ivermectin was first applied in the veterinary field for the control of internal and external parasites in livestock. Its broad-spectrum and highly effective properties quickly gained global recognition in the livestock industry. In 1987, its application expanded to the field of human public health, becoming a core treatment for tropical parasitic diseases such as onchocerciasis (river blindness) and lymphatic filariasis. Merck also launched a charitable donation project, providing related formulations free of charge to impoverished areas in Africa and Latin America, cumulatively helping hundreds of millions of people escape the suffering caused by parasitic diseases.
In the 1990s, China began introducing ivermectin fermentation technology and, through assimilation and independent innovation, gradually established a complete production system. Entering the 21st century, with the upgrading of bio-fermentation technology and the increasing global demand for parasite control, the ivermectin industry entered a period of rapid development. Its application scenarios expanded from traditional livestock and poultry farming and public health to multiple sub-sectors such as pet health, skin care, and agricultural pest control. The industry scale continued to expand, and technological levels continued to break through.
II. Industry Chain Structure: Full Chain Analysis and Characteristics of Core Links
The ivermectin industry chain presents a typical three-tiered structure: "upstream raw material supply-midstream core production-downstream application and distribution." Each link has a clear division of labor and collaborative linkage, forming a technology-intensive, policy-sensitive, and export-oriented industrial ecosystem. Among these, midstream raw material production is the core of the industry chain, with the highest technological barriers and is also the main source of industry profits. Downstream application areas directly determine the industry's demand scale and growth potential, and are significantly influenced by factors such as livestock development, public health policies, and consumption upgrades.
2.1 Upstream: Raw Material Supply and Strain Cultivation
The upstream segment mainly comprises three core areas: strain cultivation, culture medium raw material supply, and excipient procurement. The quality and stability of these areas directly impact the efficiency and product purity of midstream production. Strain cultivation is the core technology of the upstream segment, with *Streptomyces avermitilis* as the core strain. Companies in the industry optimize strain performance and improve the proportion of fermentation units and B1a components through traditional mutagenesis breeding and gene editing technologies. Currently, leading global companies have adopted CRISPR gene editing technology to modify strains, increasing B1a component purity to over 98.5% and fermentation yield by over 15%. Leading domestic companies such as North China Pharmaceutical and Hisun Pharmaceutical have established dedicated strain banks, continuously iterating and optimizing to ensure their core competitiveness.
Cultivation medium raw materials are mainly agricultural byproducts, including corn steep liquor, soybean meal, glucose, and yeast powder. These raw materials are widely available and relatively inexpensive, but their quality is significantly affected by the place of origin and processing technology. Therefore, the industry has strict requirements for raw material traceability and quality testing, which must comply with relevant GMP (Good Manufacturing Practice) standards. The procurement of excipients mainly includes Tween 80, propylene glycol, starch, and lactose, which are used for molding and stabilization in downstream formulation production. The quality of excipients must meet pharmacopoeia standards, and some high-end formulations have even higher purity requirements for excipients, relying on imports or supply from a few specialized domestic excipient companies.
The upstream industry has a relatively fragmented competitive landscape. Raw material suppliers are mainly agricultural processing companies and biological reagent companies, while strain cultivation is concentrated in a few leading companies and research institutions with R&D capabilities. Overall, the upstream segment has a relatively low technological threshold, but strict quality control requirements. Fluctuations in raw material prices directly affect the cost of midstream production. For example, the prices of corn steep liquor and soybean meal are affected by global grain market supply and demand, with an average annual fluctuation of 10%-20%, putting pressure on industry profits.
2.2 Midstream: API and Formulation Production
The midstream is the core segment of the ivermectin industry, encompassing both API production and formulation processing. It is highly technology-intensive, concentrating over 70% of the industry's R&D investment and patent portfolio. Active pharmaceutical ingredient (API) production is the core of the midstream process, and its technological route directly determines product quality, cost, and competitiveness. Currently, over 90% of ivermectin APIs globally are produced using bio-fermentation. A few companies have attempted chemical synthesis, but its high cost and pollution have prevented large-scale application.
The core process of bio-fermentation API production includes four main steps: strain activation and seed culture, fermentation culture, extraction and purification, and crystallization and drying. Fermentation culture is a critical step, requiring strict control of parameters such as temperature, pH, and dissolved oxygen concentration. Continuous fed-batch fermentation technology is used to improve fermentation efficiency. The extraction and purification stage employs technologies such as solvent extraction, column chromatography, and membrane separation to remove impurities and ineffective components from the fermentation broth, obtaining high-purity ivermectin API. The crystallization and drying stage optimizes crystallization conditions to improve product crystal stability and purity, meeting the needs of downstream formulation production. In recent years, domestic companies have achieved several technological breakthroughs through process innovation. For example, the use of membrane separation coupled with crystallization technology has reduced solvent consumption per unit product by 60% and energy consumption by 35%. Some leading companies have already built fully continuous production lines, achieving AI-driven process control and closed-loop quality management.
The formulation processing stage is the process of transforming active pharmaceutical ingredients (APIs) into usable end products. Depending on the application scenario, various formulation types are formed, mainly including tablets, topical formulations (creams, pour-over solutions, topical solutions), and feed additives (premixes, powders). Formulation production requires optimization of formulas and processes according to different application scenarios. For example, veterinary premixes need to be adapted to feed processing techniques to ensure that active ingredients are not lost during high-temperature granulation; topical creams require optimized matrix formulations to improve skin permeability and user comfort. There are 217 companies in China holding ivermectin formulation licenses, but fewer than 15 possess continuous manufacturing capabilities and high-end formulation R&D capabilities. Most companies are concentrated in low-to-mid-end, homogeneous competition.
The midstream industry exhibits an oligopolistic competitive landscape. Globally, Merck, leveraging its original technology and brand advantages, dominates the high-end API and formulation market. China, as the world's largest producer of ivermectin, has an annual API production capacity of approximately 320 tons, accounting for over 55% of global capacity. Major producers include Hisun Pharmaceutical, North China Pharmaceutical, Lu Kang Pharmaceutical, and Qilu Animal Health, collectively holding over 65% of the domestic capacity share, forming an industrial cluster centered in North China (Hebei and Shandong) and East China (Zhejiang and Jiangsu).
2.3 Downstream: Application Scenarios and Distribution Channels
The downstream segment encompasses end-user application scenarios and distribution channels. Application scenarios are divided into three core areas: veterinary, human, and agricultural. Distribution channels exhibit differentiated characteristics based on the application scenario. Downstream demand is the core driver of industry growth. In recent years, influenced by factors such as the advancement of large-scale farming, increased global public health investment, and the upgrading of pet consumption, downstream demand has continued to grow steadily, especially in the veterinary and pet sectors, where growth has been significant.
In terms of distribution channels, veterinary products are mainly sold through distributors, feed companies, and direct supply from farms. Large-scale farms primarily use direct supply, while small and medium-sized farms mainly rely on distributors. Human products are mainly sold through hospitals, primary healthcare institutions, and retail pharmacies, with some public health projects supplied through government procurement bidding. Pet products are sold through veterinary hospitals, pet supply stores, and e-commerce platforms. In recent years, with the development of e-commerce, the online sales share of pet and topical preparations has gradually increased, becoming an important growth point for the industry's distribution channels.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
III. Core Application Areas: Market Segmentation and Demand Characteristics
Ivermectin's applications are highly focused on antiparasitic and anti-inflammatory applications. The veterinary sector is the largest application market, accounting for over 80%, while the human sector primarily focuses on public health control and skin care. The agricultural sector is in its early stages, with a relatively small market size. The demand characteristics, product forms, and market drivers differ significantly across these application areas, collectively forming a diversified demand landscape within the industry.
3.1 Veterinary Sector: Largest Application Market and Growth Engine
The veterinary sector is the core application area for ivermectin. The Chinese veterinary ivermectin market is projected to reach 1.87 billion yuan by 2025, accounting for 83.1% of the total national market and also exceeding 80% of the global market. This sector primarily uses it to control internal and external parasites in animals such as cattle, sheep, pigs, poultry, and pets, including nematodes, mites, and lice. Due to its broad-spectrum, high-efficiency, and low-residue characteristics, it has become a core control product in the livestock and pet health sectors. Driven by the "antibiotic reduction and substitution" policy, its market position has been further consolidated.
From a product category perspective, cattle and sheep farming is the largest source of demand for ivermectin for veterinary use. It is primarily used to control intestinal nematodes, lungworms, and ectoparasites such as mites. Common formulations include top dressings, oral solutions, and premixes. Increased scale and density in cattle and sheep farming have led to a higher risk of parasite infection, driving up deworming frequency and consequently increasing demand for ivermectin. For example, beef cattle typically require 2-3 deworming treatments during the fattening period, while dairy cattle require regular deworming to ensure milk production and quality.
Pig farming is the second largest source of demand, primarily for controlling intestinal parasites such as roundworms, hookworms, and whipworms, as well as ectoparasites like mange mites. Common formulations include premixes and oral solutions. With the recovery of pig production capacity and the increase in large-scale farming following the African swine fever outbreak, farmers have significantly increased their focus on animal health management, leading to a continuous increase in deworming investment and driving steady growth in demand for ivermectin for pigs. In 2024, the demand for ivermectin in China's swine farming sector increased by 6.3% year-on-year, becoming a significant growth driver in the veterinary market.
Demand in the poultry farming sector was relatively small, mainly for controlling nematodes and external parasites in chickens, ducks, and geese. Common formulations were premixes and oral solutions. Due to the high scale and intensification of poultry farming, group control was often achieved through feed additives. The pet sector is a rapidly growing sub-market for veterinary ivermectin, primarily used to control external parasites (such as mites and lice) and heartworms in dogs and cats. Common formulations included topical drops and oral tablets. With the increasing number of pets in China and the upgrading of pet health consumption, the pet deworming market has seen an average annual growth rate exceeding 10%, becoming a new growth engine for the ivermectin industry.
3.2 Human Use: Dual Drivers of Public Health and Skin Care
The human ivermectin market is relatively stable, with the Chinese market size projected to reach 380 million RMB and the global market size approximately 2 billion USD by 2025. It is primarily used in two scenarios: parasitic disease control in the global public health sector and localized applications in skin care. This sector demands extremely high standards for product purity, quality stability, and safety. Manufacturers must pass stringent international certifications and domestic approvals, resulting in significantly higher technological and policy barriers compared to the veterinary sector.
The public health sector is the core application scenario for human ivermectin, primarily used to treat parasitic infections such as onchocerciasis, lymphatic filariasis, strongyloidiasis, ascariasis, and hookworm disease. Onchocerciasis and lymphatic filariasis are neglected tropical diseases that require global control, mainly prevalent in developing countries and regions such as Africa, Latin America, and Southeast Asia. Ivermectin, with its highly effective and convenient preventative properties, has become a core product recommended by the WHO for disease control. It is widely used through global public health projects, and Merck's charitable donation program has continued for decades, donating over 2 billion doses of the formulation, helping over 1 billion people worldwide escape the threat of onchocerciasis.
In China, human ivermectin is mainly used for the prevention and control of intestinal and cutaneous parasitic diseases, especially in rural areas and areas with high parasitic disease prevalence. Its application is promoted through primary healthcare institutions and public health service projects. In recent years, with improved sanitation conditions, the incidence of intestinal parasitic diseases has gradually decreased, and market demand has remained stable. Skin care is a newly emerging application area for human ivermectin in recent years. Topical creams are used to treat inflammatory papules and pustules in mild to moderate rosacea. Its core mechanism of action is to inhibit the release of inflammatory factors in the skin and reduce the number of Demodex mites. Due to its mild local effects and high safety profile, it has become an important choice for rosacea treatment, and market demand is showing a steady upward trend.
It is important to note that the application of ivermectin in the human field is subject to strict limitations. While there have been studies in recent years regarding its use in the control of other diseases, none have yet received authoritative approval. Its core applications remain focused on parasitic disease control and skin care.
3.3 Agriculture: Potential Application Scenarios and Development Prospects
Agriculture presents a potential application scenario for ivermectin, primarily for controlling pests such as mites and nematodes on crops, particularly suitable for pest control in cash crops such as vegetables, fruits, and flowers. As a bio-based insecticidal ingredient, ivermectin possesses advantages such as environmental friendliness, low resistance development, and safety to natural enemies, aligning with the trend of green agriculture and attracting industry attention in recent years.
Currently, agricultural ivermectin is mainly applied in formulations such as emulsifiable concentrates, wettable powders, and water-dispersible granules for the control of pests such as citrus red spider mites, apple leaf mites, and vegetable root-knot nematodes, with significant effects. However, due to the dispersed application scenarios in agriculture, the difficulty in controlling dosage, and the risk of residues in agricultural products, its market promotion is subject to strict policy regulation. Currently, the global market size for agricultural ivermectin is relatively small, accounting for less than 5% of the total industry size.
In the future, with the continued advancement of green agriculture policies and the rapid development of the biopesticide market, agricultural ivermectin is expected to become a new growth highlight in the industry. Industry companies are reducing residue risks, improving application efficiency, and expanding application scenarios in agriculture through formulation innovation (such as sustained-release formulations and nano-formulations) and precision drug delivery technology research and development. It is projected that the global agricultural ivermectin market will grow at an average annual rate of over 8% in the next 5-10 years, becoming an important support for the industry's diversified development.
IV. Development Trends and Future Outlook
In the next 5-10 years, driven by multiple factors such as policy support, technological innovation, and demand upgrading, the ivermectin industry will show a steady growth trend, evolving towards greening, high-end products, internationalization, and diversification. The global market size is projected to expand at an average annual growth rate of 5.8%, with the Chinese market growing slightly faster than the global average. High-end formulations, pet products, and international CDMO collaborations will be key highlights of industry growth.
4.1 Core Industry Development Trends
Green manufacturing and environmental upgrades will be an inevitable trend in industry development. Against the backdrop of increasingly stringent global environmental policies, industry players will continue to increase investment in green process R&D, promote environmentally friendly technologies such as continuous fermentation, membrane separation, and green solvents, reduce energy consumption and pollutant emissions, and achieve green and sustainable production processes. It is projected that in the next five years, the proportion of green solvents used in the domestic ivermectin industry will exceed 85%, and the coverage rate of continuous production lines will increase to over 30%. Environmental compliance will become a core prerequisite for the survival and development of enterprises.
High-end formulations and product structure upgrades will be the core drivers of industry growth. With the upgrading of downstream demand (such as the upgrading of pet health consumption and the growth in human skin care demand) and the advancement of the "antibiotic reduction and replacement" policy, the market demand for high-end formulations (sustained-release formulations, targeted formulations, and compound formulations) will grow rapidly, gradually replacing low- and mid-range homogeneous products. It is projected that over the next five years, the domestic market size for high-end ivermectin formulations will grow at an average annual rate exceeding 10%, accounting for over 25% of the overall formulation market, with a significant increase in product added value.
International expansion and high-end market development will become core strategies for leading domestic companies. Domestic enterprises will gradually increase investment in international certifications, improve CTD (Content Delivery Date) data and QbD (Quality by Design) R&D systems, enhance the alignment of product quality standards with international regulations, and gradually overcome entry barriers in highly regulated markets such as Europe, the US, and Japan. Simultaneously, they will expand their global market share and reduce the impact of trade barriers through CDMO (Content Delivery Management Organization) international cooperation and overseas production capacity layout. It is projected that over the next five years, China's ivermectin exports to high-end markets in Europe, the US, and Japan will account for over 25%, significantly optimizing the export structure.
Diversified application scenarios and expansion into niche markets will unlock industry growth potential. In addition to traditional veterinary and human applications, demand in niche scenarios such as agriculture (crop pest control), pet care (high-end deworming products), and skin care (rosacea treatment, anti-mite care) will grow rapidly, becoming new growth highlights for the industry. Especially in the pet sector, with the increase in global pet ownership and the upgrading of pet health consumption, the market size is expected to grow at an average annual rate of over 10%, becoming a significant engine for industry growth.
Technological innovation and intelligent upgrading will continue to drive industry development. New technologies such as gene editing, synthetic biology, artificial intelligence, and the Internet of Things will be deeply integrated with ivermectin production processes, promoting intelligent and efficient improvements in strains, processes, and production control. For example, AI-driven fermentation process control technology will be widely applied, improving product quality stability and production efficiency; synthetic biology technology will be used to develop original production processes, breaking through international technological barriers. Simultaneously, industry enterprises will strengthen industry-academia-research cooperation to enhance the originality and industrialization capabilities of core technologies.
4.2 Future Outlook and Investment Hotspots
Looking ahead, the ivermectin industry will maintain steady growth driven by multiple factors, including policy support (included in the "14th Five-Year Plan" as a key protected product), rising global public health demands, high-quality development of animal husbandry, and the upgrading of pet consumption. From 2026 to 2030, the global ivermectin market is projected to expand at an average annual growth rate of 5.8%, exceeding US$7 billion in 2030. The Chinese market is expected to grow at an average annual rate of 6.5%, exceeding RMB 3 billion in 2030, indicating a promising future for the industry.
Investment will focus on four key areas: First, the research and industrialization of high-end formulations, including sustained-release, targeted, and compound formulations, particularly high-end deworming formulations for pets and topical skincare formulations for humans, which are experiencing rapid market growth and high added value. Second, green manufacturing technologies and intelligent production line upgrades, including continuous fermentation, membrane separation coupled crystallization, and AI-driven process control, aligning with the industry's green and intelligent development trends. Third, CDMO international cooperation, where domestic companies leverage their cost and production capacity advantages to collaborate with international companies on CDMO projects, expanding their market share in the high-end segment. Fourth, the expansion into niche application scenarios, including green insecticides for agriculture, high-end health products for pets, and anti-mite skincare products, opening up new growth opportunities for the industry.
For companies in the industry, it is essential to strengthen three core competencies: first, technological innovation capabilities, increasing investment in the research and development of original strains and processes, and high-end formulations to break through international technological barriers; second, compliant operation capabilities, improving quality control systems and environmental protection facilities, obtaining international certifications, and connecting with the global high-end market; and third, differentiated competitive capabilities, focusing on niche markets (such as pet products and skin care products), developing distinctive products, and avoiding homogeneous competition in the low-to-mid-end market. Simultaneously, companies need to strengthen supply chain collaboration, establishing stable partnerships with upstream raw material suppliers, downstream distribution channels, and research institutions to build a core competitive advantage of "technology + standards + brand," consolidating their domestic market position while gradually moving towards the high end of the global value chain.
Conclusion
Ivermectin, as a broad-spectrum and highly effective antiparasitic active ingredient, has played an irreplaceable role in global public health control, livestock development, and pet health protection since its introduction. After decades of development, the industry has formed a complete industrial chain and diversified applications. China, as the world's largest producer and exporter of ivermectin, occupies a core position in the global industrial chain, but also faces multiple challenges, including technological gaps, international certification barriers, and intensified market competition.
In the future, with the promotion of green manufacturing technologies, the industrialization of high-end formulations, the expansion of international markets, and the exploration of niche application scenarios, the ivermectin industry will enter a stage of high-quality development, with continued expansion in industry scale, continuous improvement in technological levels, and a significant increase in product added value. For industry participants, only by focusing on technological innovation, adhering to compliant operations, and implementing differentiated competitive strategies can they seize opportunities amidst industry changes, achieve sustainable and healthy development, and make greater contributions to global parasite control, green agricultural development, and human health protection.
As a provider of premium Ivermectin CAS 70288-86-7, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Ivermectin Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.